Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 223

1.

Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib.

Ohyashiki K, Umezu T, Katagiri S, Kobayashi C, Azuma K, Tauchi T, Okabe S, Fukuoka Y, Ohyashiki JH.

Int J Mol Sci. 2016 Apr 15;17(4). pii: E570. doi: 10.3390/ijms17040570.

2.

Exosomes promote bone marrow angiogenesis in hematologic neoplasia: the role of hypoxia.

Ohyashiki JH, Umezu T, Ohyashiki K.

Curr Opin Hematol. 2016 May;23(3):268-73. doi: 10.1097/MOH.0000000000000235.

PMID:
26866730
3.

Effect of combined deferasirox and 5-azacytidine treatment on human leukemia cells in vitro.

Imanishi S, Takahashi R, Ohsuga M, Ohyashiki K, Ohyashiki JH.

Ann Hematol. 2015 Sep;94(9):1601-2. doi: 10.1007/s00277-015-2417-9. Epub 2015 Jun 6. No abstract available.

PMID:
26044890
4.

[Treatment-free molecular remission achieved by combination therapy with imatinib and IFNα in CML with BIM deletion polymorphism relapsed after stop imatinib].

Katagiri S, Tauchi T, Umezu T, Saito Y, Suguro T, Asano M, Yoshizawa S, Kitahara T, Akahane D, Tanaka Y, Fujimoto H, Okabe S, Gotoh M, Ito Y, Ohyashiki JH, Ohyashiki K.

Rinsho Ketsueki. 2015 Feb;56(2):216-9. doi: 10.11406/rinketsu.56.216. Japanese.

PMID:
25765803
5.

Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.

Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K, Ohyashiki JH.

Blood. 2014 Dec 11;124(25):3748-57. doi: 10.1182/blood-2014-05-576116. Epub 2014 Oct 15.

6.

Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely.

Ohyashiki JH, Ohtsuki K, Mizoguchi I, Yoshimoto T, Katagiri S, Umezu T, Ohyashiki K.

Drug Des Devel Ther. 2014 Aug 25;8:1151-9. doi: 10.2147/DDDT.S66812. eCollection 2014.

7.

Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse.

Yoshimoto T, Mizoguchi I, Katagiri S, Tauchi T, Furusawa JI, Chiba Y, Mizuguchi J, Ohyashiki JH, Ohyashiki K.

Oncoimmunology. 2014 May 14;3:e28861. eCollection 2014.

8.

Constitutive activation of the ATM/BRCA1 pathway prevents DNA damage-induced apoptosis in 5-azacytidine-resistant cell lines.

Imanishi S, Umezu T, Ohtsuki K, Kobayashi C, Ohyashiki K, Ohyashiki JH.

Biochem Pharmacol. 2014 Jun 1;89(3):361-9. doi: 10.1016/j.bcp.2014.03.008. Epub 2014 Mar 26.

PMID:
24680865
9.

Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells.

Tadokoro H, Umezu T, Ohyashiki K, Hirano T, Ohyashiki JH.

J Biol Chem. 2013 Nov 29;288(48):34343-51. doi: 10.1074/jbc.M113.480822. Epub 2013 Oct 16.

10.

Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib.

Mizoguchi I, Yoshimoto T, Katagiri S, Mizuguchi J, Tauchi T, Kimura Y, Inokuchi K, Ohyashiki JH, Ohyashiki K.

Cancer Sci. 2013 Sep;104(9):1146-53. doi: 10.1111/cas.12216. Epub 2013 Jul 9.

11.

Clinical relevance of plasma miR-106b levels in patients with chronic obstructive pulmonary disease.

Soeda S, Ohyashiki JH, Ohtsuki K, Umezu T, Setoguchi Y, Ohyashiki K.

Int J Mol Med. 2013 Mar;31(3):533-9. doi: 10.3892/ijmm.2013.1251. Epub 2013 Jan 21.

PMID:
23338559
12.

The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients.

Katagiri S, Umezu T, Ohyashiki JH, Ohyashiki K.

Br J Haematol. 2013 Jan;160(2):269-71. doi: 10.1111/bjh.12111. Epub 2012 Nov 1. No abstract available.

PMID:
23116058
13.

Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders.

Yoshizawa S, Ohyashiki JH, Ohyashiki M, Umezu T, Suzuki K, Inagaki A, Iida S, Ohyashiki K.

Blood Cancer J. 2012 Jan;2(1):e53. doi: 10.1038/bcj.2011.51. Epub 2012 Jan 20.

14.

Leukemia cell to endothelial cell communication via exosomal miRNAs.

Umezu T, Ohyashiki K, Kuroda M, Ohyashiki JH.

Oncogene. 2013 May 30;32(22):2747-55. doi: 10.1038/onc.2012.295. Epub 2012 Jul 16.

PMID:
22797057
15.

Telomere length shortening in patients with dementia with Lewy bodies.

Kume K, Kikukawa M, Hanyu H, Takata Y, Umahara T, Sakurai H, Kanetaka H, Ohyashiki K, Ohyashiki JH, Iwamoto T.

Eur J Neurol. 2012 Jun;19(6):905-10. doi: 10.1111/j.1468-1331.2011.03655.x. Epub 2012 Jan 31.

PMID:
22288427
16.

The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.

Ohyashiki JH, Yoneta M, Hisatomi H, Iwabuchi T, Umezu T, Ohyashiki K.

BMC Med Genet. 2012 Jan 17;13:6. doi: 10.1186/1471-2350-13-6.

17.

Age-related decrease of miRNA-92a levels in human CD8+ T-cells correlates with a reduction of naïve T lymphocytes.

Ohyashiki M, Ohyashiki JH, Hirota A, Kobayashi C, Ohyashiki K.

Immun Ageing. 2011 Nov 15;8(1):11. doi: 10.1186/1742-4933-8-11.

18.

Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib.

Ohyashiki K, Katagiri S, Tauchi T, Ohyashiki JH, Maeda Y, Matsumura I, Kyo T.

Br J Haematol. 2012 Apr;157(2):254-6. doi: 10.1111/j.1365-2141.2011.08939.x. Epub 2011 Nov 11. No abstract available.

PMID:
22077498
19.

Association between ApoE phenotypes and telomere erosion in Alzheimer's disease.

Takata Y, Kikukawa M, Hanyu H, Koyama S, Shimizu S, Umahara T, Sakurai H, Iwamoto T, Ohyashiki K, Ohyashiki JH.

J Gerontol A Biol Sci Med Sci. 2012 Apr;67(4):330-5. doi: 10.1093/gerona/glr185. Epub 2011 Oct 19.

PMID:
22016362
20.

Non-random chromosomal deletion clustering at 20q in Waldenström macroglobulinemia.

Kitahara T, Umezu T, Ando K, Kodama A, Ohyashiki JH, Ohyashiki K.

Hematology. 2011 May;16(3):139-42. doi: 10.1179/102453311X12953015767338.

PMID:
21669052
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk